BG63863B1 - Използване на производни на сулфаминовата киселина, ацил сулфонамиди или сулфамоил карбамати за получаването на средство за понижаване на липопротеиновите нива - Google Patents

Използване на производни на сулфаминовата киселина, ацил сулфонамиди или сулфамоил карбамати за получаването на средство за понижаване на липопротеиновите нива Download PDF

Info

Publication number
BG63863B1
BG63863B1 BG102222A BG10222298A BG63863B1 BG 63863 B1 BG63863 B1 BG 63863B1 BG 102222 A BG102222 A BG 102222A BG 10222298 A BG10222298 A BG 10222298A BG 63863 B1 BG63863 B1 BG 63863B1
Authority
BG
Bulgaria
Prior art keywords
methylethyl
bis
phenyl
sulfamic acid
acetyl
Prior art date
Application number
BG102222A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102222A (en
Inventor
Brian KRAUSE
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG102222A publication Critical patent/BG102222A/xx
Publication of BG63863B1 publication Critical patent/BG63863B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG102222A 1995-08-04 1998-01-30 Използване на производни на сулфаминовата киселина, ацил сулфонамиди или сулфамоил карбамати за получаването на средство за понижаване на липопротеиновите нива BG63863B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US303195P 1995-08-04 1995-08-04
PCT/US1996/011366 WO1997005868A1 (en) 1995-08-04 1996-07-08 Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels

Publications (2)

Publication Number Publication Date
BG102222A BG102222A (en) 1998-09-30
BG63863B1 true BG63863B1 (bg) 2003-04-30

Family

ID=21703764

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102222A BG63863B1 (bg) 1995-08-04 1998-01-30 Използване на производни на сулфаминовата киселина, ацил сулфонамиди или сулфамоил карбамати за получаването на средство за понижаване на липопротеиновите нива

Country Status (27)

Country Link
US (1) US6117909A (zh)
EP (1) EP0841913B1 (zh)
JP (1) JPH11510184A (zh)
KR (1) KR19990036127A (zh)
CN (1) CN1192140A (zh)
AT (1) ATE232097T1 (zh)
AU (1) AU716255B2 (zh)
BG (1) BG63863B1 (zh)
CA (1) CA2221729A1 (zh)
CZ (1) CZ26198A3 (zh)
DE (1) DE69626118T2 (zh)
DK (1) DK0841913T3 (zh)
EA (1) EA002435B1 (zh)
EE (1) EE9800037A (zh)
ES (1) ES2191762T3 (zh)
GE (1) GEP20012511B (zh)
HR (1) HRP960341A2 (zh)
HU (1) HUP9900668A3 (zh)
IL (1) IL122247A0 (zh)
NO (1) NO980466L (zh)
NZ (1) NZ312571A (zh)
PL (1) PL185943B1 (zh)
PT (1) PT841913E (zh)
SK (1) SK12598A3 (zh)
UA (1) UA46030C2 (zh)
WO (1) WO1997005868A1 (zh)
ZA (1) ZA966617B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1584333A3 (en) * 1998-01-28 2009-04-29 Warner-Lambert Company LLC Use of acetylcoenzime A inhibitors for treating Alzheimer's disease
EA200100153A1 (ru) * 1998-07-21 2001-08-27 Варнер-Ламберт Компани Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
JP2003513909A (ja) * 1999-11-05 2003-04-15 ワーナー−ランバート・カンパニー Ａｃａｔ阻害剤によるプラーク破裂の予防
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
US6939224B2 (en) * 2002-03-12 2005-09-06 Igt Gaming device having varying risk player selections
AR113878A1 (es) 2017-11-14 2020-06-24 Merck Sharp & Dohme Compuestos de biarilo sustituido como inhibidores de indolamina 2,3-dioxigenasa (ido)
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003106A (en) * 1983-07-19 1991-03-26 American Cyanamid Company Antiatherosclerotic ureas and thioureas
WO1992007826A1 (en) * 1990-10-30 1992-05-14 Warner-Lambert Company Oxysulfonyl carbamates
US5245068A (en) * 1990-10-30 1993-09-14 Warner-Lambert Company Oxysulfonyl carbamates
IL101785A0 (en) * 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds

Also Published As

Publication number Publication date
AU716255B2 (en) 2000-02-24
JPH11510184A (ja) 1999-09-07
GEP20012511B (en) 2001-08-27
AU6454196A (en) 1997-03-05
PL185943B1 (pl) 2003-09-30
US6117909A (en) 2000-09-12
EE9800037A (et) 1998-08-17
HRP960341A2 (en) 1998-02-28
PL324908A1 (en) 1998-06-22
EP0841913B1 (en) 2003-02-05
HUP9900668A3 (en) 2000-08-28
ATE232097T1 (de) 2003-02-15
EA002435B1 (ru) 2002-04-25
ES2191762T3 (es) 2003-09-16
CZ26198A3 (cs) 1998-07-15
HUP9900668A2 (hu) 1999-06-28
EA199800176A1 (ru) 1998-10-29
DE69626118D1 (de) 2003-03-13
CA2221729A1 (en) 1997-02-20
DE69626118T2 (de) 2003-11-27
DK0841913T3 (da) 2003-05-05
EP0841913A1 (en) 1998-05-20
KR19990036127A (ko) 1999-05-25
CN1192140A (zh) 1998-09-02
IL122247A0 (en) 1998-04-05
NZ312571A (en) 2000-07-28
NO980466D0 (no) 1998-02-03
SK12598A3 (en) 1999-02-11
UA46030C2 (uk) 2002-05-15
ZA966617B (en) 1997-02-18
BG102222A (en) 1998-09-30
PT841913E (pt) 2003-06-30
WO1997005868A1 (en) 1997-02-20
NO980466L (no) 1998-02-03

Similar Documents

Publication Publication Date Title
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
US5316765A (en) Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
ES2334672T3 (es) Composicion farmaceutica que comprende un combinacion de metformina y una estatina.
EP0792643B1 (en) Use of an aldose reductase inhibitor for reducing non-cardiac tissue damage
JPH11515025A (ja) 脂質濃度を調節するための方法および医薬組成物
BG63863B1 (bg) Използване на производни на сулфаминовата киселина, ацил сулфонамиди или сулфамоил карбамати за получаването на средство за понижаване на липопротеиновите нива
JP2002537258A5 (zh)
US4338334A (en) 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
CA2433409C (en) Use of mglur5 antagonists for the treatment of pruritic conditions
US20090062338A1 (en) Nitroxides for use in treating or preventing cardiovascular disease
EP0543855A1 (en) Use of aryl hydroxyurea compounds for the treatment of atherosclerosis
US7666900B2 (en) ABCA1 stabilizer
MXPA97009275A (en) Use of derivatives of sulfamic acid, acil sulfonamides or sulfonil carbamates for the manufacture of a medicinal product to reduce delipoprotei levels
WO2008060949A2 (en) Compounds with anti-androgenic activity and the use thereof
KR20020041831A (ko) 허혈성 상태로부터 유발되는 질병의 치료 또는 예방용의약 제조를 위한 2-아미노-3,4-디하이드로-퀴나졸린의 용도
CA2392187A1 (en) Combination preparation for the therapy of immunological diseases
Lamon et al. Hematin therapy in acute porphyria and observations on hemopexin
US6472430B2 (en) Amino thioxomethyl amino oxyacetic acid derivatives
WO2006064825A1 (ja) ドライアイ治療剤
JP2004250442A (ja) エンドセリン血中濃度低下剤
WO1996022096A1 (en) Pharmaceutical compositions containing bisaramil inhibiting radical production and process for preparing same
WO2005026117A1 (ja) 脳卒中再発抑制剤